The association between antibody levels before and after 7-valent pneumococcal conjugate vaccine immunization and subsequent pneumococcal infection in chronic arthritis patients

Arthritis Research and Therapy

Volumn 17, Issue 1, 2015, Pages

  Nagel, Johanna ^a   Geborek, Pierre ^a   Saxne, Tore ^a   Jönsson, Göran ^b   Englund, Martin ^b,c   Petersson, Ingemar F ^b   Nilsson, Jan Åke ^a   Truedsson, Lennart ^a   Kapetanovic, Meliha C ^a  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY   (Sweden)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

23F ANTIBODY; 6B ANTIBODY; ANTIBODY; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PNEUMOCOCCUS VACCINE; PREDNISOLONE; TUMOR NECROSIS FACTOR ANTIBODY; UNCLASSIFIED DRUG; BACTERIUM ANTIBODY; IMMUNOLOGIC FACTOR;

ADULT; AGE DISTRIBUTION; AGED; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BACTERIAL ARTHRITIS; BACTERIAL PNEUMONIA; COHORT ANALYSIS; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DAS28; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; ICD-10; IMMUNIZATION; IMMUNOSUPPRESSIVE TREATMENT; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MALE; MENINGITIS; MONOTHERAPY; OUTCOME ASSESSMENT; PNEUMOCOCCAL INFECTION; RECEIVER OPERATING CHARACTERISTIC; REFERENCE VALUE; RHEUMATOID ARTHRITIS; SENSITIVITY AND SPECIFICITY; SEPSIS; SEROTYPE; SINGLE DRUG DOSE; SPONDYLOARTHROPATHY; BLOOD; CHRONIC DISEASE; COMPLICATION; IMMUNOLOGY; MICROBIOLOGY; MIDDLE AGED; PNEUMOCOCCAL INFECTIONS; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, BACTERIAL; ARTHRITIS, RHEUMATOID; CHRONIC DISEASE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPTAVALENT PNEUMOCOCCAL CONJUGATE VACCINE; HUMANS; IMMUNIZATION; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; PNEUMOCOCCAL INFECTIONS; YOUNG ADULT;

EID: 84939269590     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/s13075-015-0636-z     Document Type: Article

References (33)

1. World Health Organization. Pneumococcal disease. Available at: http://www.who.int/immunization/topics/pneumococcal_disease/en/.
2. Said MA, Johnson HL, Nonyane BA, Deloria-Knoll M, O'Brien KL. Estimating the burden of pneumococcal pneumonia among adults: a systematic review and meta-analysis of diagnostic techniques. PLoS One. 2013;8:e60273. doi:10.1371/journal.pone.0060273.
3. Herva E, Luotonen J, Timonen M, Sibakov M, Karma P, Mäkelä PH. The effect of polyvalent pneumococcal polysaccharide vaccine on nasopharyngeal and nasal carriage of Streptococcus pneumoniae. Scand J Infect Dis. 1980;12:97-100.
4. Mykietiuk A, Carratalà J, Domininguez A, Manzur A, Fernàndez-Sabé N, Dorca J, et al. Effect of prior pneumococcal vaccination on clinical outcome of hospitalized adults with community-acquired pneumococcal pneumonia. Eur J Clin Microbiol Infect Dis. 2006;25:457-62.
5. Stein KE. Thymus-independent and thymus-dependent responses to polysaccharide antigens. J Infect Dis. 1992;165:S49-52.
6. Centers for Disease Control and Prevention. Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease--United States, 1998-2003. MMWR Morb Mortal Wkly Rep 2005; 54:893-7.
7. Eskola J, Kilpi T, Palmu A, Jokinen J, Haapakoski J, Herva E, et al. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med. 2001;344:403-9.
8. Singleton RJ, Hennessy TW, Bulkow LR, Hammitt LL, Zulz T, Hurlburt DA, et al. Invasive pneumococcal disease caused by nonvaccine serotypes among Alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. JAMA. 2007;297:1784-92.
9. Mykietiuk A, Carratalà J, Domininguez A, Manzur A, Fernàndez-Sabé N, Dorca J, et al. A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults. N Engl J Med. 2010;362:812-22.
10. Bonten M, Bolkenbaas M, Huijts S. Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA). Abstract no. 0541. Pneumonia 2014; 3:95. Available at https://pneumonia.org.au/public/journals/22/PublicFolder/ABSTRACTBOOKMASTERforwebupdated20-3-14.pdf.
11. Centers for Disease Control and Prevention. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2012; 61:816-9.
12. Tomczyk S, Bennett NM, Stoecker C, Gierke R, Moore MR, Whitney CG, et al. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥65 years: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2014;63:822-5.
13. Nagel J, Geborek P, Saxne T, Jönsson G, Englund M, Petersson IF, et al. The risk of pneumococcal infections after immunization with pneumococcal conjugate vaccine compared to non-vaccinated inflammatory arthritis patients. Scand J Rheumatol. 2015;6:1-9.
14. Mäkelä PH, Peltola H, Kayhty H, Jousimies H, Pettay O, Ruoslahti E, et al. Polysaccharide vaccines of group A Neisseria meningtitidis and Haemophilus influenzae type b: a field trial in Finland. J Infect Dis. 1977;136:S43-50.
15. Käyhty H, Peltola H, Karanko V, Mäkelä PH. The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. J Infect Dis. 1983;147:1100.
16. Plotkin SA. Correlates of protection induced by vaccination. Clin Vaccine Immunol. 2010;17:1055-65.
17. Daly H, Hill T. Use and clinical interpretation of pneumococcal antibody measurements in the evaluation of humoral immune function. Clin Vaccine Immunol. 2015;22:148-52.
18. World Health Organization. Recommendations for the production and control of pneumococcal conjugate vaccines. World Health Organ Tech Rep Ser. 2005;927:1-29.
19. Siber GR, Chang I, Baker S, Fernsten P, O'Brien KL, Santosham M, et al. Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies. Vaccine. 2007;25:3816-26.
20. Kapetanovic MC, Roseman C, Jönsson G, Truedsson L, Saxne T, Geborek P. Antibody response is reduced following vaccination with 7-valent conjugate pneumococcal vaccine in adult methotrexate-treated patients with established arthritis, but not those treated with tumor necrosis factor inhibitors. Arthritis Rheum. 2011; 63:3723-32.
21. World Health Organization. The WHO consensus pneumococcal IgG ELISA. Training manual for enzyme-linked immunosorbent assay for the quantification of Streptococcus pneumonia serotype specific IgG (Pn PS ELISA): a guide to procedures for qualification of materials and analysis of assay performance. URL: http://www.vaccine.uab.edu/ELISA%20Protocol.pdf.
22. Schisterman EF, Perkins NJ, Liu A, Bondell H. Optimal cut-point and its corresponding Youden Index to discriminate individuals using pooled blood samples. Epidemiology. 2005;16:73-81.
23. Kapetanovic MC, Roseman C, Jönsson G, Truedsson L. Heptavalent pneumococcal conjugate vaccine elicits similar antibody response as standard 23-valent polysaccharide vaccine in adult patients with RA treated with immunomodulating drugs. Clin Rheumatol. 2011; 30:1555-61.
24. Kapetanovic MC, Saxne T, Truedsson L, Geborek P. Persistence of antibody response 1.5 years after vaccination using 7-valent pneumococcal conjugate vaccine in patients with arthritis treated with different antirheumatic drugs. Arthritis Res Ther. 2013;15:R1.
25. Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Predictors of infection in rheumatoid arthritis. Arthritis Rheum. 2002;46:2294-300.
26. Smolen JS, Landewé R, Breedveld FC, Buch M, Burmester G, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014;73:492-509.
27. Salliot C, van der Heijde D. Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. Ann Rheum Dis. 2009;68:1100-4.
28. Nahm MH, Olander JV, Magyarlaki M. Identification of cross-reactive antibodies with low opsonophagocytic activity for Streptococcus pneumonia. J Infect Dis. 1997;176:698-703.
29. Huijskens EG, Koopmans M, Palmen FM, van Erkel AJ, Mulder PG, Rossen JW. The value of signs and symptoms in differentiating between bacterial, viral and mixed aetiology in patients with community-acquired pneumonia. J Med Microbiol. 2014;63:441-52.
30. Robinson K, Baughman W, Rothrock G, Barrett NL, Pass M, Lexau C, et al. Active Bacterial Core Surveillance (ABCs)/Emerging Infections Program Network. Epidemiology of Streptococcus pneumoniae infections in the U.S., 1995-1998: opportunities for prevention in the conjugate vaccine era. JAMA. 2001; 285:1729-35.
31. Grabenstein JD, Musey LK. Differences in serious clinical outcomes of infection caused by specific pneumococcal serotypes among adults. Vaccine. 2014;32:2399-405.
32. Desai SP, Turchin A, Szent-Gyorgyi LE, Weinblatt M, Coblyn J, Solomon DH, et al. Routinely measuring and reporting pneumococcal vaccination among immunosuppressed rheumatology outpatients: the first step in improving quality. Rheumatology (Oxford). 2011;50:366-72.
33. Desai SP, Lu B, Szent-Gyorgyi LE, Bogdanova AA, Turchin A, Weinblatt M, et al. Increasing pneumococcal vaccination for immunosuppressed patients: a cluster quality improvement trial. Arthritis Rheum. 2013;65:39-47.